Growing community of inventors

Madrid, Spain

Joaquin Castilla Castrillon

Average Co-Inventor Count = 14.01

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 6

Joaquin Castilla CastrillonLuis Enjuanes Sanchez (1 patent)Joaquin Castilla CastrillonJuan Plana Duran (1 patent)Joaquin Castilla CastrillonZoltán Penzes (1 patent)Joaquin Castilla CastrillonJosé Manuel Gonzalez Martinez (1 patent)Joaquin Castilla CastrillonCarlos Miguel Sanchez Sanchez (1 patent)Joaquin Castilla CastrillonMaria Muntion Saenz (1 patent)Joaquin Castilla CastrillonMaLuisa Ballesteros Jarreno (1 patent)Joaquin Castilla CastrillonJosé Manuel Sanchez Morgado (1 patent)Joaquin Castilla CastrillonAnder Izeta Parmesan (1 patent)Joaquin Castilla CastrillonCristina Smerdou Picazo (1 patent)Joaquin Castilla CastrillonIsabel Sola Gurpegui (1 patent)Joaquin Castilla CastrillonSara Alonso Villanueva (1 patent)Joaquin Castilla CastrillonAna Mendez Zunzunegui (1 patent)Joaquin Castilla CastrillonJoaquin Castilla Castrillon (1 patent)Luis Enjuanes SanchezLuis Enjuanes Sanchez (3 patents)Juan Plana DuranJuan Plana Duran (2 patents)Zoltán PenzesZoltán Penzes (1 patent)José Manuel Gonzalez MartinezJosé Manuel Gonzalez Martinez (1 patent)Carlos Miguel Sanchez SanchezCarlos Miguel Sanchez Sanchez (1 patent)Maria Muntion SaenzMaria Muntion Saenz (1 patent)MaLuisa Ballesteros JarrenoMaLuisa Ballesteros Jarreno (1 patent)José Manuel Sanchez MorgadoJosé Manuel Sanchez Morgado (1 patent)Ander Izeta ParmesanAnder Izeta Parmesan (1 patent)Cristina Smerdou PicazoCristina Smerdou Picazo (1 patent)Isabel Sola GurpeguiIsabel Sola Gurpegui (1 patent)Sara Alonso VillanuevaSara Alonso Villanueva (1 patent)Ana Mendez ZunzuneguiAna Mendez Zunzunegui (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Cyanamid Iberica, S.a. (1 from 2 patents)


1 patent:

1. 7041300 - Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/19/2025
Loading…